NL0015001WM6 - Common Stock
QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care //...
QIAstat-Dx Analyzer 2.0 mit Software-Version 1.6 ermöglicht mobilen Zugriff auf Testergebnisse, optimiert diagnostische Prozesse und verbessert die...
Gemeinsame Bildungsinitiative konzentriert sich auf die Vorteile des Interferon-Gamma-Release-Assays (IGRA) für medizinisches Fachpersonal // Aktualisierte...
Joint educational initiative to focus on Interferon Gamma Release Assay (IGRA) benefits for healthcare providers // Updated U.S. CDC guidelines mandate...
Venlo, the Netherlands, March 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its...
Door de NeuMoDx-technologie van QIAGEN kan ZIZ de openingsuren uitbreiden, thuisafname services toevoegen, kosten voor gezondheidszorg besparen en...
QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven...
Additional ecofriendly QIAwave kits for DNA and RNA extraction receive ACT Label due to greatly improved Environmental Impact Factor compared to standard...
QIAGEN Biomedical KB-AI enthält mehr als 640 Millionen biomedizinische Beziehungen, darunter Kausalzusammenhänge zwischen Genen, Krankheiten und...
Morgan Stanley upgrades Qiagen (QGEN) to Overweight from Equal-Weight noting that the valuation gap between the Dutch company and its peers could narrow. Read more here.
Zusätzliche umweltfreundliche QIAwave-Kits für DNA- und RNA-Extraktion erhalten ACT‑Label dank deutlich besserem Umweltfaktor im Vergleich zu Standard-Kits // F&E-Labor für Probentechnologien von QIAGEN in Deutschland erhält Platin-Zertifizierung von My Green Lab; Pläne für weitere Zertifizierungen am Standort festgelegt // Kunststoffverpackungen und Treibhausgasemissionen sollen im Rahmen einer umfassenden ESG-Strategie weiter verringert werden
Additional ecofriendly QIAwave kits for DNA and RNA extraction receive ACT Label due to greatly improved Environmental Impact Factor compared to standard...
Qiagen's Q4 earnings report shows in-line Non-GAAP EPS of $0.55, but misses revenue expectations by $2.09M with $503M generated (+1.0% Y/Y).
Q4 2023: Konzernumsatz von $509 Mio. (+2% bei tatsächlichen Kursen; +1% bei konstanten Wechselkursen, CER); verwässerter Gewinn je Aktie von $0,42;...
Qiagen (QGEN) stock rises 3.5% as potential buyer for the molecular testing firm reportedly lines up advisory and financing firms.
Major earnings expected after the bell on Tuesday include:Ford Motor Company (F)Gilead Sciences (GILD)Amgen (AMGN)Enphase Energy (ENPH) Snap (SNAP)Other...
Partnership aims to help shape research, education and outreach in microbiomes – the community of microorganisms within an environment // QIAGEN to provide...
Partnerschaft gestaltet Forschung, Bildung und Informationsarbeit auf dem Fachgebiet der Mikrobiome – der Gemeinschaft von Mikroorganismen in einer...
Qiagen announces details for completion of synthetic share repurchase plan, including a reverse stock split and capital repayment to shareholders.
VENLO, Niederlande, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute Einzelheiten zum Abschluss seines...
Venlo, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion...
Qiagen (QGEN) stock rises 1% as renewed takeover talks circulate.
Qiagen (QGEN) stock rises 1% as renewed takeover talks circulate.
Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for...
QIAGEN N.V. announces a plan to return $300 million to shareholders through a synthetic share repurchase combining capital repayment and stock split.
NeuMoDx CT/NG Assay designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the U.S. // U.S. ...
Kapitalrückzahlung durch synthetischen Aktienrückkauf // Rückzahlung von bis zu $300 Mio. – von Aktionärinnen und Aktionären im Jahr 2023 genehmigter...
Capital return to be conducted through synthetic share repurchase // Return of up to $300 million – maximum approved by shareholders in 2023 – designed to...
Investments into QDI to strengthen No. 1 industry position through profitable expansion into new geographic regions, market segments and enhanced product...
Investitionen in QIAGEN Digital Insights (QDI) stärken führende Branchenposition durch profitable Expansion in neue Regionen, Marktsegmente und erweiterte...
QIAGEN expands business in the Middle East with new regional headquarters in Riyadh and public health initiatives in Saudi Arabia and Oman.
QIAGEN to open regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024 to support growing presence in the region // QIAGEN signed...
QIAGEN eröffnet Anfang 2024 neue regionale Zentrale in Riad, Saudi-Arabien, um wachsende Präsenz vor Ort zu unterstützen // Absichtserklärung mit dem...